Ribazid contains Ribavirin, a synthetic nucleotide with a guanosine-like structure. The drug inhibits viral replication by interfering with RNA and DNA synthesis, ultimately inhibiting protein synthesis and viral replication. Ribazid's antiviral effect is mainly on susceptible virus-infected cells.

Treatment of respiratory syncytial virus infection currently mainly involves detecting the cause by performing a timely RSV test. After receiving the results, the patient will be advised on a treatment regimen for RSV virus.

Respiratory syncytial virus (RSV) is an important cause of acute upper and lower respiratory infections in children. It is considered the leading cause of pneumonia in infants and young children: 60% in children and 80% in children < 1 year old (according to WHO).

RSV - respiratory syncytial virus is one of the common causes of respiratory diseases in infants and young children with the ability to spread very strongly. There is currently no vaccine to protect children from this virus. RSV infection is the leading cause of bronchiolitis and pneumonia in children under two years old and it is very dangerous for children. This disease can occur year-round but is usually in the rainy season in the southern provinces or the cold season in the northern provinces.

Vu Duc Bao (in Yen Bai) was born prematurely at 34 weeks, had a cleft palate, and was infected with the respiratory syncytial virus (RSV), which resulted in serious respiratory and heart failure. The flurry of events that begin at birth can make a baby's life appear very challenging at times. After two weeks of illness, the infant was discharged on January 31, 2015, thanks to the combined efforts of doctors and nurses at Vinmec International General Hospital's Department of Neonatology